Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 388

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1A
Chunk 388
---
 LLC and USWM, LLC, but not the former individual defendants. Briefing was complete on August 21, 2024 and the  Court heard argument on the motion on August 29, 2024. The Court entered an Order that revived the claims against US WorldMeds Partners, LLC and USWM, LLC on December 5, 2024. The operative scheduling order sets the following 

Table of ContentsSupernus Pharmaceuticals, Inc.Notes to Consolidated Financial Statements (Continued)16. Commitments and Contingencies (Continued)

key deadlines: end of fact discovery January 31, 2025 (however, certain fact depositions will likely occur in the first half of February by agreement of the parties); expert discovery to conclude May 12, 2025; case dispositive motions to be filed June 2, 2025; hearing on case dispositive and Daubert motions on September 11, 2025; pretrial conference December 10, 2025; a ten-day jury trial to begin on January 5, 2026. On January 3, 2025, the Court issued an Oral Order requiring the parties to “engage in in-person mediation in good faith” and jointly select an agreed-upon mediator. The parties are working to schedule the mediation to occur in late April 2025 in compliance with Court’s Oral Order that the mediation conference “occur no later than May 2, 2025 (unless the parties stipulate to a later date and such date is approved by the Court)." 

17. Subsequent Events

In February 2025, the FDA approved ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. ONAPGO will be launched in the second quarter of 2025.The Company paid the $25 million milestone related to the FDA's approval of the SPN-830 NDA in February 2025, and expects the remaining $30 million milestone to be due and paid in 2025. Refer to Note 6, Contingent Consideration, for further information.

ITEM 9.     CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

None.

ITEM 9A.     CONTROLS AND PROCEDURES.

Attached to